Itovebi (inavolisib) — United Healthcare
Breast Cancer
Initial criteria
- Drug recognized for treatment of the cancer indication by the NCCN Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B
Approval duration
12 months